Verily signs up four big pharmas to its clinical trials platformVerily, the life sciences company owned by Google parent Alphabet, has teamed up with Novartis, Sanofi, Otsuka, and Share XVerily signs up four big pharmas to its clinical trials platformhttps://pharmaphorum.com/news/verily-signs-up-four-big-pharmas-to-its-clinical-trials-platform/
TMC inches closer to inclisiran approval with long-term safety dataThe Medicines Company (TMC) has bet the proverbial farm on cholesterol-lowering candidate inclisiran and is celebrating new safety Share XTMC inches closer to inclisiran approval with long-term safety datahttps://pharmaphorum.com/news/tmc-inches-closer-to-inclisiran-approval-with-long-term-safety-data/
AbbVie pulls phase 3 ADC trials in glioblastoma after survival missAbbVie is the latest company to have an investigational drug for glioblastoma multiforme (GBM) – an aggressive form Share XAbbVie pulls phase 3 ADC trials in glioblastoma after survival misshttps://pharmaphorum.com/news/abbvie-pulls-phase-3-adc-trials-in-glioblastoma-after-survival-miss/
Roche’s entrectinib hits the mark in paediatric cancersRoche’s entrectinib for gene fusion-positive cancers has shown promising results in a range of paediatric cancers in an Share XRoche’s entrectinib hits the mark in paediatric cancershttps://pharmaphorum.com/news/roches-entrectinib-hits-the-mark-in-paediatric-cancers/
Pfizer reports first pivotal data for Xeljanz follow-upPfizer is already a player in the JAK inhibitor anti-inflammatory category with Xeljanz, but now has the first Share XPfizer reports first pivotal data for Xeljanz follow-uphttps://pharmaphorum.com/news/pfizer-reports-pivotal-data-xeljanz/
Boehringer settles Humira lawsuit, joins biosimilar queue in USBoehringer Ingelheim was the last man standing among challengers to AbbVie’s patents on immunology blockbuster Humira but has Share XBoehringer settles Humira lawsuit, joins biosimilar queue in UShttps://pharmaphorum.com/news/boehringer-settles-humira-lawsuit-joins-biosimilar-queue-in-us/
Doctor booking firm DocPlanner raises €80m, eyes M&AOnline appointment booking firm DocPlanner has continued a healthy run of fundraisings with a €80 million Series E Share XDoctor booking firm DocPlanner raises €80m, eyes M&Ahttps://pharmaphorum.com/news/doctor-booking-firm-docplanner-raises-e80m-eyes-ma/
Gilead patent cliff looms as Teva plans generic Truvada launchGilead’s HIV blockbuster Truvada looks set to face generic competition in the US next year, a year earlier Share XGilead patent cliff looms as Teva plans generic Truvada launchhttps://pharmaphorum.com/news/gilead-patent-cliff-looms-as-teva-plans-generic-truvada-launch/
BMS’ Opdivo fails late-stage brain cancer testBristol-Myers Squibb has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo Share XBMS’ Opdivo fails late-stage brain cancer testhttps://pharmaphorum.com/news/bms-opdivo-fails-late-stage-brain-cancer-test/
